Endocannabinoids acting via CB 1 receptors (CB 1 R) play a critical role in regulating
energy homeostasis, which was the rationale for the pharmaceutical development of CB 1 R …

The endocannabinoid system (ECS) is a complex physiologic system that affects metabolic
pathways. A dysregulated ECS has been demonstrated in animal models of obesity and the …

Endogenous signaling lipids (“endocannabinoids”) functionally related to Δ9-
tetrahydrocannabinol, the psychoactive ingredient of marijuana (Cannabis), are important …

The Cannabinoid CB1 Receptor (CB1R) is involved in a variety of physiological pathways
and has long been considered a golden target for therapeutic manipulation. A large body of …

Since the discovery of rimonabant (Acomplia: 1), a large effort has been directed at the
discovery of new, potent and selective CB1R antagonists that serve as anti obesity drugs. As …

Introduction: Excessive abdominal obesity along with other risk factors results in the
metabolic syndrome, which can lead to heart disease, Type-2 diabetes, and death. The …

Therapeutics aimed at blocking the cannabinoid 1 (CB1) receptor for treatment of obesity
resulted in significant improvements in liver function, glucose uptake and pancreatic β-cell …

Rimonabant and taranabant are two extensively studied cannabinoid-1 receptor (CB1R)
inverse agonists. Their effects on in vivo peripheral tissue metabolism are generally well …

When compared with other modifiable cardiovascular risk factors, such as hypertension,
dyslipidemia and smoking, obesity remains a surprisingly puzzling condition to prevent and …

Background and purpose: Rimonabant (AcompliaTM, SR141716A), a cannabinoid CB1
receptor inverse agonist, has recently been approved for the treatment of obesity. There are …